source: pixabay.com

Experimental Treatment for Glycogen Storage Disease Type III Gets Orphan Designation in EU and US

Post author:James Moore
Post published:July 29, 2021
Post category:Glycogen storage disease type III

According to a story from Market Watch, the biopharmaceutical company Ultragenyx Pharmaceutical, Inc. recently announced that it was given Orphan Drug designation from both the US Food and Drug Administration…

Get Involved

This Men's Health Awareness month, share your authentic story with others. Raise awareness and inspire change!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Get Involved

Experimental Treatment for Glycogen Storage Disease Type III Gets Orphan Designation in EU and US

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Get Involved

Let’s Work Together!

Keep Up to Date

Learn More